about
Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinomaGenetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV InfectionsModulation of host lipid metabolism by hepatitis C virus: Role of new therapiesSTAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liverEmerging concepts in immunity to hepatitis C virus infection.Post-transcriptional regulation of interferons and their signaling pathwaysGenetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactionsElucidation of hepatitis C virus transmission and early diversification by single genome sequencingRelation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver diseaseGenome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.Hepatitis E virus persists in the presence of a type III interferon response.Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of hepatitis C virusNanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?High-resolution quantification of hepatitis C virus genome-wide mutation load and its correlation with the outcome of peginterferon-alpha2a and ribavirin combination therapyPrevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infectionPredicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers.IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapyDeciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patientsIL28B gene polymorphism SNP rs8099917 genotype GG is associated with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-1 carriers.The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs.Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta.Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patientsIL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B.Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cellsAssociation of polymorphisms in interleukin-18 and interleukin-28B genes with outcomes of hepatitis B virus infections: a meta-analysis.Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus.Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patientsDemographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico.IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients.Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort.Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis CIL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association
P2860
Q26745585-C22C05CE-47DE-4B9B-956E-854C92677217Q26768628-6EB600C1-23B3-4104-8BFD-E9A40FCE390FQ26782009-A29887CF-F4B0-45FD-AB9D-A3157F4294ABQ27000742-CCF432E1-D83F-4C9B-864C-7141B28771D4Q27002588-73B5CF26-D5F5-4FC1-8EA8-E13C61B1E96BQ27014043-7A206F34-3C46-41F7-8D9D-0A32D2739D87Q27014831-291E1D5F-3FEC-49B5-BA84-5B8D57BD2037Q28482493-23FC79A6-8464-4ED8-86E0-E38C342357C3Q28483964-329EBD02-F0C6-4DE6-95A7-5DA8489D2D8BQ29417113-30F406C0-FC06-400E-98D8-B9CCC8803C26Q30100969-4EC577F3-E045-4F3C-BFE8-931F8DD778D0Q31066011-9256DBDA-1E4D-451F-A36A-D334366B57ACQ33559298-7B03BFA9-8085-4FE1-8170-C503F8BAF3FBQ33731308-089B449C-7944-420A-B06D-D6F2903C749BQ33784107-108DF972-228F-462B-8005-70BE024A6E54Q33786026-D4915642-72A1-4D3A-9343-DEAB5DE51DF7Q33867243-90F310D7-E9AA-411B-8C61-A8AC9FC6EF87Q33948641-0BE08C2D-FBAE-4258-BB33-B504E227DD49Q33961434-887655E4-8E69-4D66-97B5-B7C9A118AA5EQ34008754-A4C88D5A-C5FD-40C6-B3D9-41E8BC84EB64Q34015054-32619FDE-A49D-4D42-8C6F-5F1237B96617Q34049322-E0547CB3-3CD0-4905-B357-7063A89297FCQ34157284-D7F7EF3E-4F00-4882-B0E2-3A88C19C2DA9Q34214760-EB3832D2-8FB1-4407-A958-103FA636384FQ34281428-1887AF38-D3B0-4125-A049-63E65D352A01Q34312139-FCA0954C-A55F-440E-A38D-0E032C57D555Q34565991-6C0D4813-6313-42FD-B3FA-15D1D1C62399Q34612816-539B7D0E-B32A-43F2-B281-75133EC6A2EAQ34699732-CA40F83E-8D65-4997-A9A1-9A9D8C8B782AQ34985468-51CA7DE3-AB24-4E46-B442-2830BA337DB8Q35025269-E4C9BA96-8D5C-40BD-80A7-B1247C9986F9Q35077010-184657C4-76A8-4115-8E78-AEAB67068002Q35112286-0357EDB4-0F83-4EF6-AA74-790A564EDDFCQ35146008-3CB981B3-6A02-4F72-92E9-3FBF17DC48C8Q35238151-39A0F6E6-2048-48B6-B5B1-E30190B9D6ABQ35249648-A077A44F-C021-4733-BF9B-64ED47FEDC22Q35356926-A958D313-6B5A-4089-9808-14C888D8952EQ35381792-F9ACF6FD-C834-4712-B910-1C4209C06DA7Q35508148-6721DC0E-3EE8-452B-953B-8C4F2C779DEEQ35532835-255CD834-3828-4239-8D70-6CE8923EAE59
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IL28B and the control of hepatitis C virus infection.
@en
IL28B and the control of hepatitis C virus infection.
@nl
type
label
IL28B and the control of hepatitis C virus infection.
@en
IL28B and the control of hepatitis C virus infection.
@nl
prefLabel
IL28B and the control of hepatitis C virus infection.
@en
IL28B and the control of hepatitis C virus infection.
@nl
P2093
P2860
P1433
P1476
IL28B and the control of hepatitis C virus infection.
@en
P2093
Ashwin Balagopal
Chloe L Thio
David L Thomas
P2860
P304
P356
10.1053/J.GASTRO.2010.10.004
P407
P577
2010-10-13T00:00:00Z